@dansfera: The ultimate insider secret for evaluating high-stakes science plays is laid bare. Betting on a single drug candidate is walking a tightrope with *zero* insurance in the backgroundโone rejection letter ends the whole story. A truly resilient biotech needs a scalable **platform** capable of generating multiple drug candidates. That diversification is the only way to insulate your investment from the failure of one key asset. This clip breaks down the essential difference between a single-shot bet and a sustainable powerhouse in the pharma world. ๐คฏ #BiotechInvesting #StockMarket #InvestingTips #PlatformTech #VentureCapital